Stay updated with breaking news from Breast Cancer Development Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
BOTHELL - Seagen Inc. today announced data from the Phase 3 HER2CLIMB-02 clinical trial of TUKYSA in combination with the antibody-drug conjugate ado-trastuzumab emtansine . The combination showed...
BOTHELL, Wash.--(BUSINESS WIRE)--Dec 6, 2023--
Seagen Inc. today announced that the Phase 3 HER2CLIMB-02 clinical trial of TUKYSA® in combination with the antibody-drug conjugate ado-trastuzumab emtansine met its primary endpoint of... -Today at 08:06 am- MarketScreener
BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) today announced that the Phase 3 HER2CLIMB-02 clinical trial of TUKYSA® (tucatinib) in combination with the antibody-drug conjugate ado-trastuzumab emtansine (Kadcyla®) met its primary endpoint of progression-free survival (PFS). Patients in the trial had u...